27. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 58-66.
28. Porsteinsson AP, Tariot PN, Erb R, Galie S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders, Am J Geriatr Psychiatry 1997; 5 (4): 344-51.
29. Profenno LA, Tariot PN: Pharmacologic Management of Agitation in Alzheimer’s Disease. Dement Geriatr Cogn Disord; Dec 2003; 17, 1-2.
30. Ragneskog H, Eriksson S, Karlsson I, Gottfries Cg: Long-term treatment of elderly individuals with emotional disturbances: An open study with citalopram. Int Psychogeriatr 1996: 8: 659-668.
31. Ramadan FH, Naughton BJ, Bassanelli Ag: treatment of agitation with a selective serotonin reuptake inhibitor. J Geriatr Psychiatry Neurol 2000; 13: 56-59.
32. Reisberg B, Ferris SH, De León MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139.
33. Rosenquist K, Tariot PN, Loy R: Treatments for behavioral and psychological symptoms in Alzheimer’s disease and other dementias; in Ames D, Burs A, O’Brien J (eds): Dementia. London, Chapman and Hall, 2000.
34. Scharre DW, Chang S: Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Disease and Associated disorders 2002; 16(2): 128-130.
35. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Ger Soc 1990; 38: 553-63.
36. Stotskey B. Multicenter study comparing thioridazine with diazepam and placebo in elderly nonpsychotic patients with emotional and behavioral disorders. Clin ther 1984; 6: 546-559.
37. Street JS, Scott Clark W, Gannon KS, Cummings JL, Bymaster FP, Tamura RN et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychia- try 2000; 57: 968-76.
38. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5(1): 60-9.
39. Taragano FE, Allegri R, Vicario A, Bagnatti P, Lyketsos CG. A double blind, randomized, fixed dose trial of fluoxetine versus amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics 1997; 38: 246-252.
40. Tariot PN. Valproate use in neuropsychiatric disorders in the elderly. Phichopharmacol Bull submitted.
41. Tariot PN, Cummings JL, Katz IR et a. A randimized, double blind, placebo controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in nursing home setting. J Am Geriatr Soc 2001; 49: 1590- 1599.
42. Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Anis J, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42: 1160-6.
43. Tariot PN, Erb R, Podgorski CA, Cox C, Pattel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61.
44. Tariot PN, Frederiksen K, Erb R, Leibovici A, Podgorski CA, Asnis J, Cox C. Lack of carbamacepine toxicity in frail nursing home patients: a controlled study. J Am Geriatr Soc 1195; 43: 1026-1029.
45. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE et al. Treatment of agitation in AD. A randomised, placebo-controlled clinical trial. Neurology 2000, 55 (9): 1247-8.
46. ZubenKo GS. Biological correlates of clinicl heterogeneity in primary dementia. Neuropsychopharmacology 1992; 6: 77-93.